aav-vector-design-agent
AAV vector design: capsid selection, promoter optimization, payload capacity.
Maintainer FreedomIntelligence · Last updated April 1, 2026
Query PharmGKB and CPIC for drug-gene interactions, pharmacogenomic annotations, and dosing guidelines. Use when predicting drug response from genetic variants or implementing clinical pharmacogenomics.
Original source
https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills/tree/main/skills/bio-clinical-databases-pharmacogenomics
Skill Snapshot
Source Doc
Goal: Determine metabolizer phenotype from CYP star allele diplotypes using CPIC activity scores.
Approach: Sum per-allele activity scores and classify into PM/IM/NM/UM categories based on CPIC thresholds.
Goal: Check whether a specific drug-gene-variant combination has a known pharmacogenomic interaction.
Approach: Query PharmGKB variant annotation endpoint filtered by drug and gene, then match to the target variant.
| Gene | Drugs | Clinical Impact |
|---|---|---|
| CYP2D6 | Codeine, tamoxifen, ondansetron | Efficacy, toxicity |
| CYP2C19 | Clopidogrel, omeprazole, escitalopram | Efficacy, dosing |
| CYP2C9 | Warfarin, phenytoin, NSAIDs | Bleeding risk, dosing |
| VKORC1 | Warfarin | Dosing |
| TPMT | Azathioprine, mercaptopurine | Myelosuppression |
| DPYD | Fluorouracil, capecitabine | Severe toxicity |
| HLA-B*57:01 | Abacavir | Hypersensitivity |
| HLA-B*15:02 | Carbamazepine | SJS/TEN |
| SLCO1B1 | Simvastatin | Myopathy risk |
| UGT1A1 | Irinotecan | Neutropenia |
Related skills
AAV vector design: capsid selection, promoter optimization, payload capacity.
AgentD autonomous drug discovery: target identification, hit finding, ADMET optimization.
Call HLA alleles from NGS data using OptiType, HLA-HD, or arcasHLA for immunogenomics applications. Use when determining HLA genotype for tr…
Cell-free RNA analysis: plasma cfRNA profiling for liquid biopsy diagnostics.